Denmark
Denmark's Lundbeck to buy Longboard Pharma in $2.6 billion deal
The companies said Lundbeck will acquire all of Longboard's shares for $60 per share, which represents a premium of 54.2% to the stock's last close of $38.90. Longboard's lead drug candidate, bexicaserin, for seizures associated with a group of epile
The com... [365 chars]